研究文章
药物涂层球囊新创冠状动脉病变:系统回顾和审判顺序随机对照试验的荟萃分析
|
| 研究中,年 |
样本大小,DCB /控制 |
病人的迹象 |
类型的DCB |
救助支架 |
对照组 |
男(%),DCB /控制 |
年龄 |
HBP (%), DCB /控制, |
DM (%), DCB /控制 |
最大的福 |
Jadad评分 |
| DCB |
控制 |
|
| BASKET-SMALL2 2018 (18] |
382/376 |
圣言会 |
SQP |
5.10% |
PES / ee |
77% / 70% |
|
|
85% / 89% |
32% / 35% |
12个月 |
3 |
| 贝罗,201212] |
90/92 |
圣言会 |
在。协议猎鹰 |
20.20% |
PES |
80% / 77.2% |
|
|
80% / 81.5% |
43.3% / 38.0% |
3年 |
3 |
| 首次亮相,201910] |
102/106 |
HRB |
SQP |
2% |
百时美施贵宝 |
62% / 64% |
|
|
87% / 91% |
26% / 49% |
3年 |
3 |
| Funatsu 2017 (20.] |
92/41 |
圣言会 |
SQP |
2.90% |
POBA |
78% / 68% |
|
|
84% / 73% |
48% / 32% |
6个月 |
3 |
| Gobić2017 (19] |
38/37 |
STEMI |
SQP |
7.30% |
SES |
70.7% / 73% |
|
|
31.7% / 35.1% |
4.9% / 10.8% |
6个月 |
3 |
| 他,201621] |
27/33 |
新创 |
SQP |
10% |
ee |
74.1% / 72.7% |
|
|
76.7% / 90% |
40.0% / 43.3% |
8月的年代 |
3 |
| PEPCAD-BIF 2015 (22] |
32/32 |
BIF-SVD |
SQP |
0% |
POBA |
75.0% / 71.9% |
|
|
NA |
34.4% / 37.5% |
9个月 |
3 |
| PEPCAD-NSTEMI 2019 (9] |
104/106 |
NSTEMI |
SQP |
14.60% |
BMS / DES |
66.3% / 67.9% |
|
|
78.7% / 87.7% |
26.9% / 35.8% |
9个月 |
3 |
| PICCOLETO 2010 (13] |
28/29 |
圣言会 |
迪奥 |
34.50% |
PES |
78.6% / 75.9% |
|
|
75.0% / 70.8% |
37.9% / 46.4% |
9个月 |
3 |
| 中国恢复圣言,201817] |
116/114 |
圣言会 |
恢复 |
4.00% |
ZES |
66.4% / 77.2% |
|
|
67.2% / 75.4% |
39.7% / 42.1% |
1年 |
3 |
| 启示,201911] |
59/61 |
STEMI |
Pantera勒克斯 |
18% |
SES |
87% / 87% |
|
|
30% / 32% |
13% / 17% |
9个月 |
3 |
| 心,201916] |
20/20 |
HRB |
SQP |
0% |
百时美施贵宝 |
70.0% / 75% |
|
|
40% / 45% |
35% / 25% |
12个月 |
3 |
|
|
|
药物涂层气球调查:SQP =后继请(B。德国布劳恩,Melsungen)。协议猎鹰(美敦力公司,高威,爱尔兰),此款勒克斯(Biotronik,柏林,德国),迪奥(Eurocor、波恩、德国),和恢复(Cardionovum、波恩、德国)。百时美施贵宝:裸金属支架;DES:药物洗脱支架;ee: verolimus-eluting支架;傅:随访;哈佛商业评论:病人出血风险高;以上非st段抬高心肌梗死NSTEMI:;PES:紫杉醇洗脱支架;POBA:普通球囊成形术; BIF-SVD: side branch bifurcation lesion with small vessel disease; SES: sirolimus-eluting stents; STEMI: ST-segment elevation myocardial infarction; SVD: small vessel disease; ZES: zotarolimus-eluting stent; HBP: hypertension; DM: diabetes mellitus; NA: not available.
|
